FDA management and enforcement: hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, first session, September 12, 1991, Volume 4
United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations
U.S. Government Printing Office, 1992 - Political Science - 388 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
aAaq action advertising Agency ANDA Work Group approval process Astrue autoimmune disease baxba Benson bioequivalence blockbuster drugs carbamazepine CDER CDRH Center for Drug Chairman chemistry review chemists Chesemore Chris Wallace collagen injections Commissioner compliance connective tissue diseases Counsel criminal debarment developed Dingell Director document draft Drug Administration drug applications drug approval Drug Evaluation Eckart effective enforcement Evaluation and Research FDA's firms Food and Drug fraud policy Group Mtg Health implemented Initiative injectable collagen inspection investigation issues Kessler Kusserow labeling manufacturing manufacturing practices medical device patients pharmaceutical physicians PM/DM problems pxnoqa question regulations regulatory request response review process Rowland Section seizure September 12 Shiley Shiley's staff Subcommittee submitted uaaq valve zidovudine